Ashley Frazer-Abel
Concepts (337)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 17 | 2025 | 326 | 4.010 |
Why?
| | Complement Activation | 14 | 2025 | 412 | 1.400 |
Why?
| | Laboratories | 3 | 2024 | 109 | 0.970 |
Why?
| | Complement Factor B | 6 | 2025 | 106 | 0.800 |
Why?
| | Immunoassay | 2 | 2021 | 108 | 0.690 |
Why?
| | Macular Degeneration | 4 | 2025 | 196 | 0.600 |
Why?
| | Clinical Laboratory Techniques | 2 | 2018 | 96 | 0.600 |
Why?
| | Laboratories, Hospital | 1 | 2018 | 14 | 0.560 |
Why?
| | Anti-Citrullinated Protein Antibodies | 4 | 2026 | 129 | 0.540 |
Why?
| | Oligonucleotides, Antisense | 3 | 2025 | 122 | 0.530 |
Why?
| | Blood Chemical Analysis | 1 | 2018 | 109 | 0.520 |
Why?
| | RNA, Transfer | 3 | 2008 | 142 | 0.490 |
Why?
| | Angioedemas, Hereditary | 2 | 2014 | 4 | 0.450 |
Why?
| | Kidney Diseases | 3 | 2025 | 428 | 0.410 |
Why?
| | RNA | 3 | 2008 | 926 | 0.390 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2023 | 992 | 0.390 |
Why?
| | Arthritis, Rheumatoid | 4 | 2026 | 1185 | 0.370 |
Why?
| | Autoimmune Diseases | 4 | 2022 | 467 | 0.370 |
Why?
| | Nucleic Acid Conformation | 4 | 2008 | 724 | 0.370 |
Why?
| | Anticodon | 3 | 2004 | 24 | 0.370 |
Why?
| | Wet Macular Degeneration | 2 | 2025 | 63 | 0.350 |
Why?
| | Angioedema | 1 | 2011 | 16 | 0.340 |
Why?
| | Geographic Atrophy | 2 | 2025 | 105 | 0.330 |
Why?
| | Complement Inactivating Agents | 2 | 2025 | 78 | 0.330 |
Why?
| | Emergency Responders | 2 | 2021 | 38 | 0.320 |
Why?
| | Humans | 56 | 2026 | 146342 | 0.300 |
Why?
| | Immunologic Tests | 2 | 2021 | 16 | 0.300 |
Why?
| | Cyclin-Dependent Kinase 4 | 3 | 2006 | 52 | 0.290 |
Why?
| | Autoantibodies | 3 | 2021 | 1500 | 0.290 |
Why?
| | T-Lymphocytes | 3 | 2009 | 2012 | 0.280 |
Why?
| | Complement Pathway, Alternative | 3 | 2025 | 123 | 0.280 |
Why?
| | Diabetic Retinopathy | 2 | 2022 | 211 | 0.280 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2019 | 134 | 0.280 |
Why?
| | Specimen Handling | 2 | 2022 | 178 | 0.280 |
Why?
| | Autoimmunity | 2 | 2025 | 925 | 0.250 |
Why?
| | Smoking | 3 | 2019 | 1486 | 0.250 |
Why?
| | Tars | 1 | 2006 | 5 | 0.240 |
Why?
| | Complement Factor H | 2 | 2019 | 81 | 0.230 |
Why?
| | Nicotine | 2 | 2009 | 337 | 0.230 |
Why?
| | Glomerulonephritis, IGA | 1 | 2025 | 14 | 0.230 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2006 | 49 | 0.230 |
Why?
| | Hydroxychloroquine | 1 | 2026 | 65 | 0.220 |
Why?
| | Inflammation | 5 | 2026 | 2919 | 0.220 |
Why?
| | Thionucleotides | 1 | 2025 | 35 | 0.220 |
Why?
| | Choroid | 1 | 2025 | 81 | 0.220 |
Why?
| | Complement C3a | 3 | 2019 | 40 | 0.220 |
Why?
| | RNA, Transfer, Ser | 2 | 2008 | 4 | 0.220 |
Why?
| | Cell Cycle | 2 | 2006 | 595 | 0.210 |
Why?
| | B-Cell Activating Factor | 1 | 2024 | 21 | 0.210 |
Why?
| | Complement Factor D | 1 | 2024 | 28 | 0.210 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 78 | 0.200 |
Why?
| | Nuclear Proteins | 3 | 2004 | 740 | 0.200 |
Why?
| | Complement C3 | 3 | 2025 | 195 | 0.200 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 1 | 2023 | 23 | 0.200 |
Why?
| | Scleroderma, Systemic | 1 | 2024 | 124 | 0.200 |
Why?
| | Quality Control | 2 | 2021 | 163 | 0.190 |
Why?
| | Biomarkers | 6 | 2026 | 4340 | 0.190 |
Why?
| | Disease Susceptibility | 4 | 2020 | 339 | 0.190 |
Why?
| | Vitreous Body | 2 | 2022 | 118 | 0.190 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2023 | 28 | 0.190 |
Why?
| | Quantitative Trait Loci | 1 | 2025 | 388 | 0.190 |
Why?
| | Antirheumatic Agents | 1 | 2026 | 309 | 0.190 |
Why?
| | Trichloroethylene | 1 | 2022 | 8 | 0.180 |
Why?
| | Muscular Dystrophy, Facioscapulohumeral | 1 | 2022 | 29 | 0.170 |
Why?
| | Protein Aggregates | 2 | 2019 | 87 | 0.170 |
Why?
| | Neuromyelitis Optica | 1 | 2023 | 135 | 0.170 |
Why?
| | Complement Inactivator Proteins | 1 | 2021 | 39 | 0.170 |
Why?
| | Extracellular Traps | 1 | 2021 | 54 | 0.170 |
Why?
| | Cross Reactions | 1 | 2021 | 130 | 0.170 |
Why?
| | Reference Standards | 1 | 2021 | 176 | 0.160 |
Why?
| | Europe | 2 | 2020 | 421 | 0.160 |
Why?
| | Retinal Drusen | 1 | 2021 | 31 | 0.160 |
Why?
| | Immunologic Factors | 2 | 2022 | 244 | 0.160 |
Why?
| | Magnesium | 4 | 2008 | 155 | 0.160 |
Why?
| | Health Status | 1 | 2026 | 827 | 0.160 |
Why?
| | DNA-Binding Proteins | 3 | 2004 | 1468 | 0.160 |
Why?
| | Sputum | 1 | 2021 | 302 | 0.150 |
Why?
| | Transcription Factors | 4 | 2004 | 1730 | 0.150 |
Why?
| | Alzheimer Disease | 1 | 2026 | 641 | 0.150 |
Why?
| | Polyvinyl Chloride | 1 | 2019 | 12 | 0.150 |
Why?
| | Diethylhexyl Phthalate | 1 | 2019 | 13 | 0.150 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 38 | 0.150 |
Why?
| | Male | 23 | 2026 | 73396 | 0.140 |
Why?
| | Islets of Langerhans | 1 | 2025 | 852 | 0.140 |
Why?
| | Female | 24 | 2026 | 79499 | 0.140 |
Why?
| | Insulin-Secreting Cells | 1 | 2023 | 393 | 0.140 |
Why?
| | Rheumatoid Factor | 1 | 2019 | 177 | 0.140 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 57 | 0.140 |
Why?
| | Biological Products | 1 | 2022 | 258 | 0.140 |
Why?
| | Mass Spectrometry | 1 | 2021 | 729 | 0.140 |
Why?
| | Occupational Exposure | 1 | 2022 | 356 | 0.140 |
Why?
| | Mitochondria, Heart | 1 | 1999 | 107 | 0.130 |
Why?
| | Aged | 12 | 2026 | 26432 | 0.130 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2025 | 3930 | 0.130 |
Why?
| | Tomography, Optical Coherence | 3 | 2025 | 283 | 0.130 |
Why?
| | Middle Aged | 14 | 2026 | 36619 | 0.120 |
Why?
| | Aged, 80 and over | 6 | 2026 | 8391 | 0.120 |
Why?
| | Complement C3 Nephritic Factor | 1 | 2016 | 1 | 0.120 |
Why?
| | Complement C5 | 1 | 2016 | 33 | 0.120 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 101 | 0.120 |
Why?
| | Riboflavin | 1 | 2016 | 15 | 0.120 |
Why?
| | Virus Inactivation | 1 | 2016 | 13 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2240 | 0.120 |
Why?
| | Blood | 1 | 2016 | 107 | 0.110 |
Why?
| | Base Sequence | 4 | 2008 | 2123 | 0.110 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2015 | 43 | 0.110 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2016 | 82 | 0.110 |
Why?
| | RNA, Fungal | 3 | 2008 | 71 | 0.110 |
Why?
| | Ebolavirus | 1 | 2016 | 91 | 0.110 |
Why?
| | Aging | 1 | 2026 | 1996 | 0.110 |
Why?
| | Critical Illness | 1 | 2021 | 908 | 0.110 |
Why?
| | RNA, Transfer, Phe | 2 | 2008 | 9 | 0.110 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2014 | 12 | 0.110 |
Why?
| | Animals | 11 | 2022 | 38106 | 0.110 |
Why?
| | Oligoribonucleotides | 1 | 2014 | 53 | 0.110 |
Why?
| | Disinfection | 1 | 2016 | 131 | 0.100 |
Why?
| | Proto-Oncogene Proteins | 3 | 2004 | 616 | 0.100 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2008 | 326 | 0.100 |
Why?
| | Birefringence | 3 | 2004 | 6 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 866 | 0.100 |
Why?
| | Adult | 12 | 2026 | 41087 | 0.100 |
Why?
| | Double-Blind Method | 3 | 2026 | 2070 | 0.100 |
Why?
| | Disease Progression | 4 | 2025 | 2867 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1101 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 376 | 0.100 |
Why?
| | Antibodies, Viral | 3 | 2022 | 689 | 0.090 |
Why?
| | Nanoparticles | 1 | 2019 | 523 | 0.090 |
Why?
| | Comprehension | 1 | 2014 | 175 | 0.090 |
Why?
| | Pyrrolidinones | 1 | 2012 | 29 | 0.090 |
Why?
| | Molecular Sequence Data | 5 | 2014 | 2838 | 0.090 |
Why?
| | Risk Factors | 5 | 2026 | 10921 | 0.090 |
Why?
| | Cyclin-Dependent Kinases | 2 | 2004 | 121 | 0.090 |
Why?
| | Cattle | 2 | 2008 | 940 | 0.090 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2011 | 6 | 0.090 |
Why?
| | Complement C4 | 1 | 2011 | 31 | 0.090 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 171 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2020 | 3647 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2012 | 508 | 0.070 |
Why?
| | Oligonucleotides | 2 | 2014 | 155 | 0.070 |
Why?
| | Mutation | 2 | 2020 | 4093 | 0.070 |
Why?
| | Complement C5a | 2 | 2019 | 54 | 0.070 |
Why?
| | Drug Packaging | 2 | 2019 | 41 | 0.070 |
Why?
| | Nicotinic Agonists | 1 | 2009 | 140 | 0.070 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2012 | 339 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2008 | 190 | 0.070 |
Why?
| | Particle Size | 2 | 2019 | 386 | 0.070 |
Why?
| | Phenotype | 3 | 2022 | 3206 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2006 | 4118 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1503 | 0.060 |
Why?
| | Immunoglobulin G | 2 | 2022 | 901 | 0.060 |
Why?
| | NFATC Transcription Factors | 2 | 2004 | 93 | 0.060 |
Why?
| | Lymphocyte Activation | 2 | 2012 | 1137 | 0.060 |
Why?
| | Resting Phase, Cell Cycle | 1 | 2006 | 16 | 0.060 |
Why?
| | Chemokine CXCL5 | 1 | 2026 | 20 | 0.060 |
Why?
| | Cell Survival | 1 | 2009 | 1105 | 0.060 |
Why?
| | Chemokine CXCL9 | 1 | 2026 | 38 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2006 | 87 | 0.060 |
Why?
| | G1 Phase | 1 | 2006 | 64 | 0.060 |
Why?
| | Kidney | 2 | 2025 | 1498 | 0.060 |
Why?
| | Proteinuria | 1 | 2025 | 103 | 0.060 |
Why?
| | Macaca fascicularis | 2 | 2016 | 70 | 0.060 |
Why?
| | Phenols | 1 | 2006 | 106 | 0.060 |
Why?
| | Temperature | 1 | 2008 | 635 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 846 | 0.050 |
Why?
| | Chromosome Mapping | 1 | 2025 | 508 | 0.050 |
Why?
| | Peptides, Cyclic | 1 | 2026 | 276 | 0.050 |
Why?
| | Hemangiosarcoma | 1 | 2004 | 27 | 0.050 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2004 | 92 | 0.050 |
Why?
| | Young Adult | 4 | 2025 | 14330 | 0.050 |
Why?
| | Plasmids | 1 | 2004 | 373 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2025 | 5439 | 0.050 |
Why?
| | Amyloid beta-Peptides | 1 | 2026 | 251 | 0.050 |
Why?
| | Rare Diseases | 1 | 2023 | 117 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2026 | 781 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Dog Diseases | 1 | 2004 | 140 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 287 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5899 | 0.040 |
Why?
| | Antibodies, Antinuclear | 1 | 2022 | 60 | 0.040 |
Why?
| | Aqueous Humor | 1 | 2022 | 41 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2025 | 745 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2026 | 784 | 0.040 |
Why?
| | Time Factors | 2 | 2025 | 7109 | 0.040 |
Why?
| | World Health Organization | 1 | 2022 | 104 | 0.040 |
Why?
| | Cytokines | 2 | 2012 | 2081 | 0.040 |
Why?
| | Albumins | 1 | 2022 | 120 | 0.040 |
Why?
| | Adolescent | 5 | 2025 | 22557 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2002 | 2599 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 182 | 0.040 |
Why?
| | Apoptosis | 1 | 2009 | 2439 | 0.040 |
Why?
| | Microspheres | 1 | 2021 | 142 | 0.040 |
Why?
| | Pancreas | 1 | 2023 | 343 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2022 | 129 | 0.040 |
Why?
| | Colorado | 2 | 2021 | 4595 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2019 | 545 | 0.040 |
Why?
| | United States | 1 | 2018 | 16136 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2024 | 571 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 284 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2004 | 2791 | 0.040 |
Why?
| | RNA, Bacterial | 1 | 2001 | 183 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2025 | 2113 | 0.040 |
Why?
| | Vitrectomy | 1 | 2020 | 74 | 0.040 |
Why?
| | Child | 4 | 2025 | 22693 | 0.040 |
Why?
| | Complement C4a | 1 | 2019 | 9 | 0.040 |
Why?
| | Freezing | 1 | 2019 | 83 | 0.040 |
Why?
| | Plasticizers | 1 | 2019 | 18 | 0.040 |
Why?
| | Syringes | 1 | 2019 | 53 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 124 | 0.040 |
Why?
| | Drug Contamination | 1 | 2019 | 56 | 0.040 |
Why?
| | South Carolina | 1 | 2019 | 46 | 0.040 |
Why?
| | Cations, Divalent | 1 | 1999 | 46 | 0.040 |
Why?
| | Drug Compounding | 1 | 2019 | 106 | 0.040 |
Why?
| | Rheology | 1 | 2019 | 94 | 0.040 |
Why?
| | Drug Stability | 1 | 2019 | 172 | 0.040 |
Why?
| | Yeasts | 1 | 1999 | 54 | 0.040 |
Why?
| | Protein Stability | 1 | 2019 | 180 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2006 | 2502 | 0.030 |
Why?
| | Surface Properties | 1 | 2019 | 384 | 0.030 |
Why?
| | Calcium | 1 | 2004 | 1181 | 0.030 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 197 | 0.030 |
Why?
| | Pituitary Gland, Anterior | 1 | 1997 | 37 | 0.030 |
Why?
| | Complement Pathway, Classical | 1 | 2017 | 18 | 0.030 |
Why?
| | Thrombotic Microangiopathies | 1 | 2017 | 19 | 0.030 |
Why?
| | Prolactin | 1 | 1997 | 88 | 0.030 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 23 | 0.030 |
Why?
| | Body Mass Index | 2 | 2019 | 2458 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1997 | 93 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2019 | 497 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 474 | 0.030 |
Why?
| | Promoter Regions, Genetic | 2 | 2002 | 1242 | 0.030 |
Why?
| | Mice | 3 | 2022 | 18297 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1339 | 0.030 |
Why?
| | Epitopes | 1 | 2019 | 479 | 0.030 |
Why?
| | Escherichia coli | 1 | 2001 | 832 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 492 | 0.030 |
Why?
| | HIV Infections | 1 | 2012 | 3215 | 0.030 |
Why?
| | Jurkat Cells | 2 | 2009 | 115 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2025 | 2488 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 1077 | 0.030 |
Why?
| | Motivation | 1 | 2021 | 605 | 0.030 |
Why?
| | Fibroblast Growth Factors | 1 | 1997 | 187 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2024 | 2921 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 651 | 0.030 |
Why?
| | Vero Cells | 1 | 2016 | 84 | 0.030 |
Why?
| | Complement C5b | 1 | 2015 | 5 | 0.030 |
Why?
| | Child, Preschool | 2 | 2025 | 11913 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 907 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 925 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2017 | 241 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2020 | 770 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 447 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2014 | 2092 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2022 | 3017 | 0.030 |
Why?
| | Quality Assurance, Health Care | 1 | 2016 | 349 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2025 | 17438 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1463 | 0.030 |
Why?
| | Logistic Models | 1 | 2019 | 2126 | 0.020 |
Why?
| | RNA Polymerase II | 1 | 1997 | 347 | 0.020 |
Why?
| | Signal Transduction | 3 | 2009 | 5246 | 0.020 |
Why?
| | Binding Sites | 3 | 2002 | 1309 | 0.020 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1997 | 411 | 0.020 |
Why?
| | Hypertension, Pulmonary | 1 | 2024 | 1957 | 0.020 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 10 | 0.020 |
Why?
| | CD4-CD8 Ratio | 1 | 2012 | 23 | 0.020 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 365 | 0.020 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 19 | 0.020 |
Why?
| | Raltegravir Potassium | 1 | 2012 | 18 | 0.020 |
Why?
| | Chemokine CCL5 | 1 | 2012 | 40 | 0.020 |
Why?
| | Funnel Chest | 1 | 2012 | 31 | 0.020 |
Why?
| | Adipokines | 1 | 2012 | 56 | 0.020 |
Why?
| | Insulin | 1 | 2023 | 2525 | 0.020 |
Why?
| | Cell Division | 2 | 2004 | 736 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1591 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1818 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3347 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2012 | 278 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11821 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2022 | 0.020 |
Why?
| | Viral Load | 1 | 2012 | 526 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2012 | 369 | 0.020 |
Why?
| | Leukemia, T-Cell | 1 | 2009 | 5 | 0.020 |
Why?
| | Scoliosis | 1 | 2012 | 231 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 8123 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1849 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2012 | 642 | 0.020 |
Why?
| | Transfection | 2 | 2002 | 916 | 0.020 |
Why?
| | Receptors, Nicotinic | 1 | 2009 | 337 | 0.020 |
Why?
| | Pilot Projects | 1 | 2012 | 1888 | 0.020 |
Why?
| | HIV-1 | 1 | 2012 | 913 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 931 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 1150 | 0.010 |
Why?
| | Ploidies | 1 | 2004 | 21 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 2004 | 160 | 0.010 |
Why?
| | Protein Binding | 2 | 2001 | 2244 | 0.010 |
Why?
| | Precipitin Tests | 1 | 2002 | 90 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2004 | 447 | 0.010 |
Why?
| | Dogs | 1 | 2004 | 517 | 0.010 |
Why?
| | Luciferases | 1 | 2002 | 153 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2002 | 275 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2002 | 526 | 0.010 |
Why?
| | Cyclosporine | 1 | 2002 | 256 | 0.010 |
Why?
| | Tacrolimus | 1 | 2002 | 192 | 0.010 |
Why?
| | Exons | 1 | 2002 | 361 | 0.010 |
Why?
| | Base Pairing | 1 | 2001 | 65 | 0.010 |
Why?
| | Histone Deacetylases | 1 | 2002 | 208 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 560 | 0.010 |
Why?
| | Lymphocytes | 1 | 2002 | 379 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2002 | 369 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 974 | 0.010 |
Why?
| | RNA Stability | 1 | 2001 | 119 | 0.010 |
Why?
| | Models, Genetic | 1 | 2002 | 540 | 0.010 |
Why?
| | Ribosomes | 1 | 2001 | 196 | 0.010 |
Why?
| | Cell Movement | 1 | 2004 | 951 | 0.010 |
Why?
| | Chromatin | 1 | 2002 | 559 | 0.010 |
Why?
| | Phosphorylation | 1 | 2002 | 1724 | 0.010 |
Why?
| | Transcription Factor Pit-1 | 1 | 1997 | 26 | 0.010 |
Why?
| | Fibroblast Growth Factor 4 | 1 | 1997 | 19 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1997 | 46 | 0.010 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 1 | 1997 | 26 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 1997 | 54 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2004 | 952 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2002 | 2134 | 0.010 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 165 | 0.010 |
Why?
| | Genes, Fungal | 1 | 1997 | 55 | 0.010 |
Why?
| | Coenzymes | 1 | 1997 | 23 | 0.010 |
Why?
| | Catalysis | 1 | 1997 | 304 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1761 | 0.010 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 1997 | 250 | 0.010 |
Why?
| | Gene Expression Regulation, Fungal | 1 | 1997 | 79 | 0.010 |
Why?
| | Fungal Proteins | 1 | 1997 | 137 | 0.010 |
Why?
| | Mediator Complex | 1 | 1997 | 61 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2004 | 3545 | 0.010 |
Why?
| | Models, Molecular | 1 | 2001 | 1573 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1997 | 882 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1997 | 429 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1997 | 525 | 0.010 |
Why?
| | Rats | 1 | 1997 | 5586 | 0.000 |
Why?
|
|
Frazer-Abel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|